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Negative exponential modelWe attempted to quantify the decline in stroke risk following quitting using the negative exponential
model, with methodology previously employed for IHD. We identiﬁed 22 blocks of RRs (from 13 studies)
comparing current smokers, former smokers (by time quit) and never smokers. Corresponding pseudo-
numbers of cases and controls/at risk formed the data for model-ﬁtting. We tried to estimate the half-life
(H, time since quit when the excess risk becomes half that for a continuing smoker) for each block. The
method failed to converge or produced very variable estimates of H in nine blocks with a current smoker
RR <1.40. Rejecting these, and combining blocks by amount smoked in one study where problems arose
in model-ﬁtting, the ﬁnal analyses used 11 blocks. Goodness-of-ﬁt was adequate for each block, the com-
bined estimate of H being 4.78(95%CI 2.17–10.50) years. However, considerable heterogeneity existed,
unexplained by any factor studied, with the random-effects estimate 3.08(1.32–7.16). Sensitivity analy-
ses allowing for reverse causation or differing assumed times for the ﬁnal quitting period gave similar
results. The estimates of H are similar for stroke and IHD, and the individual estimates similarly hetero-
geneous. Fitting the model is harder for stroke, due to its weaker association with smoking.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
In 1989, the US Surgeon-General concluded smoking causes
stroke (US Surgeon General, 1989). The same year, a meta-analysis
(Shinton and Beevers, 1989) concluded there was strong evidence
of an excess risk, though varying by type of stroke, most evident for
cerebral infarction and subarachnoid haemorrhage. The authors
noted an excess risk of stroke in former smokers, but did not quan-
tify how this declined by time quit. Some authorities subsequently
made statements about this. The 1990 review of ‘‘The Health Ben-
eﬁts of Smoking Cessation’’ (US Surgeon General, 1990a) concluded
that ‘‘After cessation, the excess risk decreases steadily. In some
studies, the risk of stroke among former smokers becomes indistin-
guishable from that of never smokers within 5 years; in otherstudies, this decrease did not occur until after 10 years or more
of smoking abstinence.’’ More recently, the International Agency
for Research on Cancer (IARC) Monograph ‘‘Reversal of risk after
quitting smoking’’ (International Agency for Research on Cancer,
2007) examined the evidence in detail, noting that ‘‘Studies that
have assessed the relationship of the duration of smoking absti-
nence on stroke risk report a marked risk reduction in 2–5 years
after cessation, and the risk reduction continues up to 15 years
after quitting. In some studies the risk declines to the level of never
smokers within 5–10 years, but some studies report increased risk
–though markedly lower than among continuous smokers – even
after 15 years of abstinence.’’ This review noted various methodo-
logical issues in assessing this evidence, including reverse causa-
tion, with some smokers quitting because of disease, and
difﬁculties in accurately assessing smoking habits.
No one has previously attempted to quantify precisely the
decline in excess stroke risk following quitting, using all available
evidence and a formal model-ﬁtting procedure. As in our earlier
papers in this journal on the effects of smoking cessation on
ischaemic heart disease (IHD) (Lee et al., 2012) and lung cancer
(Fry et al., 2013), we use the negative exponential model to charac-
terize the shape of the curve for each dataset by a single parameter.
This parameter, the half-life (H), is the time since quitting when
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Individual values of H can be used to assess between-study heter-
ogeneity, and make overall estimates.2. Methods
2.1. Inclusion and exclusion criteria
Attention was restricted to epidemiological prospective or
case–control studies presenting data by time of quitting smoking
on mortality or incidence of stroke (or types of stroke). The data
had to be in a form allowing ﬁtting of the negative exponential
model, as described in Section 2.5 below. Studies of effects of quit-
ting following a stroke were excluded, as were studies only pre-
senting results for total cardiovascular disease, including IHD.2.2. Literature searches
In April 2010, A PubMed search was conducted using the search
terms ‘‘(stroke or cerebrovascular disease) and (quitting smoking
or smoking cessation)’’, with abstracts inspected to identify possi-
bly relevant publications. Additional relevant papers were sought
from the IARCmonograph on quitting (International Agency for Re-
search on Cancer, 2007), the US Surgeon General report on quitting
(US Surgeon General, 1990b), and papers identiﬁed in our similar
review on IHD and quitting (Lee et al., 2012). In October 2011, an
additional PubMed search was undertaken, using the search terms
‘‘(stroke or cerebrovascular disease or subarachnoid haemorrhage
or intracerebral haemorrhage or cerebral infarction) and (quitting
smoking or smoking cessation or former smoking or ex-smoking)’’.
To avoid overlap with the previous search, this was limited to
papers published since 1st January 2009. Finally, the April 2010
search was repeated, using the expanded search terms given
above.2.3. Identiﬁcation of studies
Relevant papers were allocated to studies, accounting for multi-
ple papers from the same study, and papers reporting on multiple
studies. Each study was given a unique reference code (REF) of up
to 6 characters, based on the name of the principal author or of the
study. Care was taken to check whether different studies involved
the same groups of subjects, thus avoiding double-counting in the
meta-analyses. Where necessary, additional study details were
obtained from other publications.2.4. Data recorded
For each study, relevant information was entered onto a study
database and a linked relative risk (RR) database. Note that,
throughout this paper, we use the term RR to include its various
estimators, including the odds ratio and hazard ratio. The study
database contains a record per study containing data equivalent
to those recorded for IHD (Lee et al., 2012). The data on the RR
database relates to sequences of RRs (‘‘blocks’’). A block consists
of a current smoker RR and a set of former smoker RRs by period
of quitting, each RR being expressed relative to never smokers.
Where originally expressed relative to current smokers, RRs were
converted to be relative to never smokers, usually by the method
of Hamling et al. (2008). The data recorded per RR were as de-
scribed for IHD (Lee et al., 2012).2.5. Statistical methods
The main features of the methods, described more fully previ-
ously (Lee et al., 2012), are summarized below.2.5.1. Pseudo-numbers
We used the method of Hamling et al. (2008) to estimate the
pseudo-table of the numbers of cases and the numbers either in
the at risk population (for prospective studies) or of controls (for
case–control studies) that correspond to the observed RRs and
95% conﬁdence intervals (CIs). This forms the data for ﬁtting the
negative exponential distribution.2.5.2. Estimated time quit
For each quitting period given in the source papers, we used the
mid-point of the lower and upper times of quitting to estimate the
time quit tj to be used in the modelling. For the ﬁnal, ‘‘open-ended
above’’, quitting group we used the mean of the lower limit and
either 50 years or the upper limit of the age range studied minus
20 years. tj is taken as inﬁnite for never smokers and zero for cur-
rent smokers.2.5.3. Fitting the negative exponential distribution to each block
For prospective studies, the underlying model, ﬁtted to the data
by maximum likelihood methods, is Pj = A + B exp (Ctj), where Pj
is the absolute risk of disease at time tj in group j, and A, B and C are
parameters to be estimated. A is the risk in never smokers, A + B
that in current smokers, and B the increase in risk for current
smoking. H is estimated by H = (loge2)/C. Goodness-of-ﬁt to the
model was assessed from the difference in log-likelihood between
the ﬁtted and the best-ﬁt model.
For case–control studies, the model used is Fj = 1 + B exp (Ctj),
where Fj is the RR (compared to never smokers) rather than the
absolute risk. While C is interpreted as for prospective studies, B
is not, being the excess relative rather than absolute risk.2.5.4. Regression analyses
Sources of heterogeneity were studied by inverse-variance
weighted regression of log H, between-block variation in log H
being examined by study type, sex, continent, publication year,
mean age of subjects studied, smoking product, current smoking
RR, and numbers of cases in quitters.2.5.5. Sensitivity analyses
Sensitivity analyses A and B investigated the dependence of H
on possible ‘‘reverse causation’’. In A, the group with the shortest
quitting time was omitted from each block. In B, all groups with
an upper limit of quitting time <2 years were reallocated as current
smokers. Sensitivity analyses C and D studied the effect of using
time estimates for the ﬁnal, open-ended, quitting group, based
on algorithms alternative to that described in section the value
of 50 years in that algorithm being replaced by either 30 years
(C) or 70 years (S4).2.5.6. Software
Data entry and most analyses were carried out using ROELEE
version 3.1 (available from P.N. Lee Statistics and Computing Ltd.,
17 Cedar Road, Sutton, Surrey SM2 5DA, UK), some analyses using
Excel 2003.
P.N. Lee et al. / Regulatory Toxicology and Pharmacology 68 (2014) 85–95 873. Results
3.1. Searches
The ﬁrst stage of the searches in April 2010 identiﬁed 36 publi-
cations as possibly relevant, the later searches identifying 42 more.
Examining reference lists led to identifying another 11 possibly
suitable papers, while cross-referencing with the papers included
in the IHD project gave two more. Another publication came from
our in-house referencing system after searching for additional pa-
pers on a study already identiﬁed.3.2. Studies identiﬁed
Of the 92 publications identiﬁed as possibly relevant, 60 were
rejected at an early stage as they only contained information on
former smokers in total, not by quitting time, or were reviews with
no original data. This left 32 publications apparently satisfying the
inclusion and exclusion criteria, or giving background information
not in the main reference. However, 14 were later rejected for var-
ious reasons. One (Hsu and Pwu, 2004) was due to insufﬁcient data
on numbers of events and person-years at risk, one (Rogot and
Murray, 1980) as the data were in a form too difﬁcult to use, and
ﬁve (Álvarez et al., 2011; Bjartveit and Tverdal, 2009; Godtfredsen
et al., 2002; Song and Cho, 2008; Vollset et al., 2006) as the former
smokers were not split by time of quitting at baseline, but by
whether they had quit during a deﬁned period. One study (LaCroix
et al., 1991) used the endpoint total cardiovascular disease, not
stroke, one (Petoumenos et al., 2011) concerned HIV patients, with
results only for coronary heart disease and total cardiovascular
disease, one (Hjermann et al., 1981) compared stroke incidence
between a usual care and a smoking cessation group, rather than
between quitters and continuing smokers, one (Henley et al.,
2004) only gave data for pipe smokers only, and two (Bell and
Symon, 1979; Wolf et al., 1988) did not provide data in a form
allowing analysis, although relevant information was collected.
Finally, one study (Kenﬁeld et al., 2010) duplicated an existing
study.
The 18 remaining publications divided into 13 studies. Table 1
gives selected details of these studies. Note that HONJO is based
on a combined analysis of three studies, individual results from
one (Iso et al., 2005) not included to avoid double-counting.
Of the 13 studies, ﬁve were in the USA, three in Japan, three in
Australasia, one in Great Britain, and one involving seven countries.
There was no material overlap between populations in different
studies. The results relate to males in three studies, females in
one, and both sexes in nine. Ten were prospective studies, fol-
low-up periods ranging from 4 to 25 years, and three case–control
studies with population controls. Of the three, two were of sub-
arachnoid haemorrhage, and one of cerebral ischaemia. The pro-
spective studies all used an endpoint called stroke or
cerebrovascular disease, only two including any nonfatal cases.
One of the studies, NURSES, also presented results separately for
subarachnoid haemorrhage and ischaemic stroke. Three studies
started in the 1950s or 1960s, three in the 1970s, four in the
1980s and three on or after 1990.3.3. Blocks considered in the analysis
Table 2 gives details of the 22 blocks originally selected for anal-
ysis. Of the 13 studies, six provided only one block (three for males,
one for females and two for sexes combined), six provided results
by sex, and one provided blocks jointly by sex and level of con-
sumption. Eleven blocks related to smoking of cigarettes, regard-
less of pipes and cigars, four to smoking of cigarettes only, andsix to smoking of any product. The RRs were adjusted for age in
all 22 blocks, and for additional non-smoking variables (see
footnote d of Table 2 for details) in 12 blocks from nine studies.
Pseudo-numbers of cases in quitters ranged from 10.0 to 847.6
(median 52.5). The 22 current smoking RRs were heterogeneous
(v2 = 329.46 on 21 degrees of freedom (DF), p < 0.001), ranging
from 0.85 to 6.30. Although 11 RRs exceeded 2, nine were below
1.40, with one below 1.0.
Numbers of quitting groups ranged from two to eight, most
commonly three (seven blocks). Generally, quitting periods were
as reported at time of interview in case–control studies, or at base-
line in prospective studies, with no updating of the time as follow-
up progressed. However, in NURSES quitting time was updated at
intervals based on the latest information available, with RRs re-
ported relating to the most recent quitting period. Quitting time
was updated during follow-up in CPS I, HONJO and KAISER. In most
studies, length of time quit did not affect the deﬁnition of a former
smoker. However, CPS I and KAISER excluded quitters of less than
2 years, although not apparently reallocating them to the current
smoking group, while ACROSS counted those quitting in the previ-
ous year among the current smoker group. Also, BRHS and HIRAYA
appeared to have excluded quitters of less than one year, while
DONNAN excluded those quitting in the previous 3 months,
although it is unclear how these subjects were classiﬁed. LONGST
related stroke risk to time last smoked a cigarette, and included
results for extremely short periods of 0–3 and 4–24 h. As subjects
in these groups were not quitters as usually deﬁned, they were
included among the current smokers in our analyses.
As shown in Table 2, some available data sets were not included
in analysis, to avoid overlap, and to avoid data sets where the only
available quitter RRs were relative to current smokers, and
adjusted for other smoking variables, as one cannot similarly
adjust never smoker RRs relative to current smokers. Exceptionally,
data from CPS I adjusted for amount smoked were included, no
other data from this study being available.
3.4. Rejection of blocks
Initial analyses revealed problems in ﬁtting the model to those
nine blocks with a current smoker RR <1.40, some of which (blocks
16, 17, 18 and 22) reported no statistically signiﬁcant increase with
current smoking. For three of these blocks (12, 27 and 22) the
method failed to converge, while most of the other blocks pro-
duced estimates of H with very large SEs (and hence small weight
in any meta-analysis). Problems also arose ﬁtting the CPS II data
split by amount smoked; particularly for heavy smokers, where
the data showed a strange pattern of RRs with no evidence of a
monotonic decline in risk. We therefore decided to restrict the ﬁnal
analysis to blocks with a current smoker RRP 1.40, and that, for
CPS II, the analysis should use blocks not split by amount smoked.
For completeness, Table 3 shows, for the rejected blocks and the
CPS II blocks by amount smoked, RRs and 95%CIs as well as
observed number of cases for each level estimated from the
pseudo-numbers.
3.5. Fitting the negative exponential model to the 11 selected blocks
Table 4 shows, for each selected block, and for two additional
blocks by type of stroke for study NURSES, the data used for
model-ﬁtting, including the complete set of RRs and CIs (expressed
relative to never smokers), the pseudo-numbers of cases corre-
sponding to these RRs (‘‘cases observed’’), and the estimated values
of the times quit. Table 4 also gives results of ﬁtting the model to
each block separately, showing the ﬁtted RR values (again relative
to never smokers), the ﬁtted numbers of cases, the estimate of H
and its SE, and the goodness-of-ﬁt chi-squared value, v2(ﬁt),
Table 1
Selected details of the 13 studies.
Study Refa
Main Refb
Location Sex Study
typec
Start
year(s)d
Follow-up
yearse
Out-
comef
Fatalityg Commentsh
ACROSS
Anderson et al. (2004)
Australia/New
Zealand
M + F CCP 1995–98 – SAH B ACROSS study in Adelaide, Auckland, Hobart
and Perth
BRHS
Wannamethee et al.
(1995)
GB M P 1978–80 13 S B British regional heart study
CPS I
Burns et al. (1997)
USA M + F P 1959–60 12 CVD F ACS 25 state study
CPS II
US Surgeon General
(1990a)i
USA M + F P 1982 4 CVD F ACS 50 state study
DONNAN
Donnan et al. (1989)
Australia M + F CCP 1985–88 – CI B 4 hospitals in Melbourne
HIRAYA
Hirayama (1990)
Japan M + F P 1965 17 CVD F Six prefectures
HONJO
Honjo et al. (2010)j
Japan M + F P 1983–90 10 S F Pooled analysis of 3 studies
JAMROZ
Jamrozik et al. (2011)
Australia M + F P 1996 10 S F Females from ALSWH
Males from HIMS
KAISER
Friedman et al. (1997)
USA M + F P 1979–86 6 S F Kaiser permanente, California
KONDO
Kondo et al. (2011)
Japan M P 2000 8 S B Workers undergoing annual check-ups
LONGST
Longstreth, Jr. et al.
(1992)
USA M + F CCP 1987–89 – SAH B Washington state
NURSES
Kenﬁeld et al. (2008)k
USA F P 1976–04 24 Sl Fm Nurses’ health study
SEVENC
Jacobs, Jr. et al.
(1999)n
7 countrieso M P 1957–64 25 S F Seven countries study
a Six character reference code used.
b Additional references giving results by time of quit are indicated against the speciﬁc studies.
c CCP = case–control study with population controls, P = prospective study.
d Range of years when the case–control study was conducted or the baseline period for prospective studies.
e Only applicable to prospective studies. The longest period for which any publication reported results.
f CI = cerebral ischaemia, CVD = cerebrovascular disease, S = stroke, SAH = subarachnoid haemorrhage.
g B = both fatal and non-fatal cases, F = fatal cases, NF = non-fatal cases.
h Abbreviations used: ACROSS = Australasian Cooperative Research On Subarachnoid haemorrhage Study, ACS = American Cancer Society, ALSWH = Australian Longitudinal
Study on Women’s Health, HIMS = Health in Men Study.
i Additional references (Taylor et al., 2002; Thun et al., 1997).
j Additional reference (Iso et al., 2005).
k Additional reference (Kawachi et al., 1993).
l Results also available for SAH and ischaemic stroke but not considered in the main analysis.
m Results also available for fatal and non-fatal events combined but not analyzed.
n Additional reference (Menotti et al., 2001).
o Finland, Greece, Italy, Netherlands, Croatia and Serbia (former Yugoslavia), Japan, USA.
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value. Two additional ﬁles give further information. Additional ﬁle
1: Estimates gives further details of the ﬁt, including ﬁtted values
of A and B, and the full variance/covariance matrix of the estimates.
Additional ﬁle 2: Plots graphically displays the goodness-of-ﬁt for
each block.
Model ﬁt is generally good, with pP 0.05 in all blocks. The
strongest evidence of misﬁt is for CPS II males (blocks 6 and 7 com-
bined), where p is 0.09. Here, there was clear evidence of a decline
in RR in the ﬁrst few years of quitting, followed by an increase and
then a later decline. Note the data for CPS II females show an odd
pattern, with the risk below that of never smokers within a few
years of quitting and staying below regardless of time quit. The
estimated H for this block of 0.04 years had an extremely high SE
of 258.75, so contributes little to the inverse-variance weighted
overall estimates.
Fig. 1, a forest plot, gives ﬁtted H values and their 95%CI for each
block individually and overall. There is evident heterogeneity be-
tween the estimates of H, which in ascending order are 0.04,
0.25, 0.88, 1.15, 1.18, 1.32, 2.21, 3.44, 7.71, 15.11 and 17.74. The
heterogeneity chisquared based on inverse-variance weightedregression analysis of log H is estimated at 36.89 on 10 DF
(p < 0.001). The overall estimate of H from this analysis, equivalent
to a ﬁxed-effects estimate, is 4.78 (95%CI 2.17–10.50) years. Table 5
shows no signiﬁcant variation in H by any factor studied in the
meta-regression analyses. However, the tendency for H to rise with
increasing age at baseline seen for IHD (Lee et al., 2012) is to some
extent apparent for stroke. A random-effect estimate of H is 3.08
(95%CI 1.32–7.16) years.
The heterogeneity was emphasised further by additional analy-
ses (results not shown) in which a ﬁxed value of 4.78 (the weighted
mean) was ﬁtted to each block. A signiﬁcant misﬁt (p < 0.05) was
seen in four blocks – in blocks 3, 8 + 9, and 21 because the best-ﬁt-
ting H value was less than 4.78, and in block 6 + 7 because it was
more than 4.78.
3.6. Sensitivity analyses
Table 6 compares ﬁtted H values and goodness-of-ﬁt for the
main and for all four sensitivity analyses, A and B testing for
dependence of H on ‘‘reverse causation’’, and C and D studying
the effect of using alternative time estimates for the ﬁnal group
Table 2
Details of the 22 blocks eligible for analysis.
Blocka Study Refb Sex Age Exposurec Adjustedd Current smoker RR Cases in quitterse Quitting groups (years)f
1 ACROSS M 15+ Any product Age + 7 3.60 32.7 1–4, 5–15, >15g
2 F 6.30 28.3
3 BRHS M 40–59 Cigarettes Age + 9 3.70 33.7 1–5, 6–10, 11–19, 20+
4 CPS I M 35+ Cigarettes only Age + 1 1.24 847.6 2–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39h
5 F 1.06 251.2
6 CPS II M 30+ Cigarettes <21/day Age 2.43 150.9 <1, 1–2, 3–5, 6–10, 11–15, 16+
7 21+/day 2.07 137.5
8 F Cigarettes < 20/day 1.77 19.2
9 20+/day 2.33 10.0
10 DONNAN M + F 20–87 Any product Age + 1 3.70 87.6 <2, 2–5, 5–10, >10
11 HIRAYA M 40+ Cigarettes Age 1.08 253.1 1–4, 5–9, 10+
12 F 1.18 32.6
13 HONJO M 40–79 Any product Age + 1 1.25 425.2 <2, 2–4, 5–9, 10–14, 15+
14 F 1.69 38.0
15 JAMROZ M 65–79 Any product Age + 4 2.15 147.7 0–5, 6–10, 11–20, >20
16 F 70–75 1.18 67.1
17 KAISER M 35+ Cigarettes only Age 1.37 21.9 2–10, 11–20, >20h
18 F 0.85 12.4
19 KONDO M 20–61 Cigarettes Age + 3 2.17 10.8 <4, 4+
20 LONGST M + F 18+ Cigarettes Age, sex + 1 6.01 29.8 0–3 h, 4–24 h, >1 day–1 year, >1–10 years, >10 years
21 NURSESi F 30–55 Cigarettes Age 2.78 216.5 <5, 5–<10, 10–<15, 15–<20, 20+
22 SEVENC M 40–59 Cigarettes Age + 1 1.13 135.1 <1, 1–9, >10
a Where there is no entry in a column for a block, the value is that given in the next completed row above.
b Details of data not used in the analysis, with reasons for omission, are as follows: HONJO – The data adjusted for smoking variables were not used. The data are combined
results from three studies. To avoid overlap, data from one of the individual studies (Iso et al., 2005) was not used. NURSES – The multivariate data including adjustment for
age of starting to smoke were not used. The data from Kawachi et al. (1993) were not used as based on a shorter follow-up.
c ‘‘Cigarettes’’ = cigarettes ± other products (pipes and cigars), ‘‘Any product’’ = cigarettes and/or other products.
d Age + n (or Age, sex + n) indicates the number of other non smoking risk factors that were adjusted for: ACROSS – Race, study centre, use of proxy respondent, history of
hypertension, diabetes, alcohol use; BMI BRHS – BMI, physical activity, alcohol, social class, diabetes, pre-existing IHD, antihypertensive treatment, blood pressure, cho-
lesterol; CPS I – Amount smoked; DONNAN – Hypertension; HONJO – Cohort; JAMROZ – Area, country of birth, education, marital status; KONDO – Blood pressure,
cholesterol, glucose; LONGST – Respondent type; SEVENC – Cohort.
e Estimated pseudo-numbers (Hamling et al., 2008).
f Based on time of interview for case–control and time of baseline interview for prospective studies, except that for prospective study NURSES the time of quit was updated
at intervals based on repeat interviews. Exceptionally, in study CPS I, and probably study HONJO, the time of quit in subjects was recategorized during follow-up. Thus a
subject reporting having quit for 4 years at baseline, would have been counted as having quit for 9 years, 5 years later.
g Quitters for less than a year were included among the current smokers.
h Only quitters of at least 2 years were considered to be former smokers.
i The data given are for all stroke. Additional data are available for subarachnoid haemorrhage, where the current smoker RR was 5.00 and the quitting groups were <2, 2–4,
5–14 and 15+ years, and for ischaemic stroke, where the current smoker RR was 2.27 and the quitting groups were <2, 2–4, 5–9, 10–14 and 15+ years.
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quitting time are removed from analysis, estimates of H are gener-
ally quite similar to those from the main analysis. The most evident
exception is block 19, where removal of the block for <4 years quit-
ting left only one RR for quitting, the estimate of H increasing from
0.88 to 8.17 years. This contributed to the increase in the overall
estimate from 4.78 to 6.40 years. As for the main analysis, no block
showed signiﬁcant model misﬁt in analysis A.
In analysis B, RRs for quitting periods up to 2 years are counted
as relating to current smokers. This had no effect for four blocks,
but meant omission of one or more RRs in the other seven. This lit-
tle affected the estimate of H except for block 20 (LONGST) where
it increased from 0.25 to 4.22. The overall estimate increased
slightly, from 4.78 to 5.55 years, but again there was no evidence
of misﬁt.
In analysis C the midpoint time was reduced in each block,
while in D it was increased in eight blocks and unchanged in three.
With some exceptions, the general effect was to decrease estimates
of H slightly in analysis C and increase them in D. Overall estimates
of H changed little, however, being 4.61 years for C and 4.80 years
for D, compared to 4.78 years for the main analysis. There was no
evidence of misﬁt for C or D.
3.7. Type of stroke
Of the 11 blocks selected for analysis in Table 5, three (blocks 1,
2 and 20) relate to subarachnoid haemorrhage and one (block 10)
relates to cerebral ischaemia. The rest, as do all the rejected blocks(Table 3), relate to overall risk of stroke or cerebrovascular disease.
In view of the differing relationships between smoking and type of
stroke, with current smoking RR typically highest for subarachnoid
haemorrhage, intermediate for ischaemic stroke, and lowest for
cerebral haemorrhage (Kawachi et al., 1993; US Surgeon General,
2004), it is of interest to consider whether H may vary by type.
Here, the additional data from study NURSES (see Table 4), not in-
cluded in the main analyses to avoid double-counting, are relevant.
For subarachnoid haemorrhage, there is some evidence that Hmay
be lower than our overall estimate of 4.78, with values of 1.15,
1.18, 0.25 and 3.01 from blocks 1, 2, 20 and 23, respectively. How-
ever, for none of these blocks did the overall estimate signiﬁcantly
(p < 0.05) misﬁt the data. The evidence for other types of stroke is
even more limited, with an estimate of H of 15.11 for cerebral
ischaemia from block 10 and of 0.38 for ischaemic stroke from
block 24. While the overall estimate of 4.78 is not consistent (at
p < 0.05) with the ﬁrst estimate, it is inconsistent (p = 0.003) with
the second.
4. Discussion
As noted earlier (Lee et al., 2012), when reporting on quitting
and IHD, the negative exponential model has many attractions,
including its simple functional form, easily understood interpreta-
tion, and possible application to data for a variety of smoking-
related diseases, and to studying effects of switching to a reduced
daily consumption or a reduced exposure product. That paper
includes extensive discussion of various problems affecting
Table 3
Data for rejected blocks and for CPS II blocks later combined.
Block: study Sex Age Smoking group Years quit RR (95%CI)a Cases observedb
4: CPS I M 35+ Current 1.24 (1.18–1.31) 4777.52
Ex 3.5 1.62 (1.43–1.84) 274.41
Ex 7.5 1.16 (0.99–1.36) 164.68
Ex 12.5 1.05 (0.88–1.25) 132.82
Ex 17.5 1.01 (0.83–1.22) 104.34
Ex 22.5 0.93 (0.74–1.17) 75.89
Ex 27.5 0.78 (0.59–1.04) 48.93
Ex 32.5 0.80 (0.57–1.13) 33.31
Ex 37.5 0.65 (0.38–1.12) 13.22
Never 1.00 1988.51
5: CPS I F 35+ Current 1.06 (1.00–1.12) 1757.95
Ex 3.5 2.28 (1.86–2.79) 95.51
Ex 7.5 1.18 (0.87–1.59) 42.66
Ex 12.5 1.25 (0.91–1.71) 38.94
Ex 17.5 1.01 (0.69–1.48) 26.53
Ex 22.5 1.11 (0.74–1.67) 23.30
Ex 27.5 0.84 (0.49–1.44) 13.25
Ex 32.5 0.57 (0.26–1.27) 6.11
Ex 37.5 0.92 (0.38–2.25) 4.86
Never 1.00 3725.67
6: CPS II M 30+ Current 2.43 (1.99–2.96) 192.15
(<21 cigarettes/day) Ex 0.5 3.94 (2.69–5.78) 30.11
Ex 2.0 1.11 (0.46–2.69) 5.04
Ex 4.5 1.55 (0.94–2.54) 16.84
Ex 8.5 1.64 (1.13–2.37) 32.56
Ex 13.5 0.62 (0.37–1.05) 15.20
Ex 33.0 0.72 (0.53–0.98) 51.20
Never 1.00 196.63
7: CPS II M 30+ Current 2.07 (1.67–2.56) 147.62
(21 + cigarettes/day) Ex 0.5 0.37 (0.09–1.49) 1.97
Ex 2.0 1.43 (0.53–3.84) 3.99
Ex 4.5 1.39 (0.79–2.44) 12.85
Ex 8.5 2.27 (1.52–3.39) 27.11
Ex 13.5 2.34 (1.65–3.32) 37.32
Ex 33.0 1.92 (1.42–2.59) 54.23
Never 1.00 194.79
8: CPS II F 30+ Current 1.77 (1.14–2.74) 24.83
(<20 cigarettes/day) Ex 1.5 1.13 (0.16–8.10) 1.01
Ex 4.5 0.79 (0.11–5.66) 1.00
Ex 8.5 0.59 (0.15–2.39) 2.04
Ex 13.5 1.23 (0.50–3.02) 4.98
Ex 33.0 0.93 (0.49–1.78) 10.15
Never 1.00 101.99
9: CPS II F 30+ Current 2.33 (1.66–3.26) 48.31
(20 + cigarettes/day) Ex 0.5 0.29 (0.04–2.08) 0.99
Ex 2.0 0.51 (0.07–3.65) 0.99
Ex 4.5 0.71 (0.18–2.88) 2.03
Ex 8.5 0.84 (0.21–3.40) 2.02
Ex 13.5 0.23 (0.03–1.65) 0.97
Ex 33.0 0.73 (0.23–2.30) 2.97
Never 1.00 111.55
11: HIRAYA M 40+ Current 1.08 (1.02–1.14) 6802.84
Ex 3.0 1.22 (1.02–1.45) 134.58
Ex 7.5 0.82 (0.63–1.07) 56.63
Ex 30.0 0.80 (0.62–1.03) 61.87
Never 1.00 1511.85
12: HIRAYA F 40+ Current 1.18 (1.09–1.27) 749.32
Ex 3.0 1.50 (0.91–2.47) 15.39
Ex 7.5 1.49 (0.75–2.95) 8.17
Ex 30.0 1.16 (0.84–3.10) 8.99
Never 1.00 5251.37
13: HONJO M 40–79 Current 1.25 (1.10–1.42) 1180.18
Ex 1.0 1.35 (0.95–1.92) 34.13
Ex 3.5 1.21 (0.96–1.53) 88.91
Ex 7.5 1.13 (0.90–1.40) 106.46
Ex 12.5 0.81 (0.62–1.06) 62.95
Ex 32.5 0.76 (0.62–0.93) 132.78
Never 1.00 315.85
16: JAMROZ F 70–75 Current 1.18 (0.74–1.87) 19.88
Ex 3.0 0.99 (0.52–1.88) 9.73
Ex 8.5 0.89 (0.45–1.73) 8.83
Ex 15.5 1.18 (0.77–1.79) 24.74
Ex 35.5 0.89 (0.58–1.37) 23.84
Never 1.00 140.46
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Table 3 (continued)
Block: study Sex Age Smoking group Years quit RR (95%CI)a Cases observedb
17: KAISER M 35+ Current 0.85 (0.43–1.67) 11.61
Ex 6.5 1.40 (0.50–3.94) 4.10
Ex 15.5 1.20 (0.56–2.59) 8.40
Ex 35.0 0.90 (0.43–1.87) 9.35
Never 1.00 29.65
18: KAISER F 35+ Current 1.37 (0.83–2.26) 23.04
Ex 6.5 0.30 (0.04–2.16) 0.99
Ex 15.5 1.20 (0.52–2.77) 6.24
Ex 35.0 0.90 (0.36–2.23) 5.14
Never 1.00 45.60
22: SEVENC M 40–59 Current 1.13 (0.95–1.34) 507.40
Ex 0.5 1.53 (1.03–2.25) 26.96
Ex 5.5 1.04 (0.78–1.37) 63.62
Ex 24.5 1.23 (0.89–1.69) 44.50
Never 1.00 161.12
a The sources of these data are as follows: Blocks 4,5,6,7,8,9,17,18-RRs as given, CIs estimated from numbers and person-years, Blocks 11,12-RRs as given, 95%CIs estimated
from 90% CIs, Block 13-RRs and CIs given with current smoker base recalculated with a never smoker base using the pseudo-numbers, Block 16-RRs and CIs as given, Block 2-
RRs and CIs derived from numbers.
b Estimated pseudo-numbers of cases (Hamling et al., 2008). Corresponding values for the controls and at risk population are available on request.
Table 4
Fit of the negative exponential model to the data for the 11 blocks selected and for two additional blocks from study NURSES.
Block: studya Sexb Agec Smoking group Years quit RR (95%CI)d Fitted RR Cases observede Cases ﬁttedf
1: ACROSS M 15+ Current 3.60 (1.70–7.50) 4.45 62.74 62.70
Ex 3.0 1.20 (0.30–4.50) 1.57 4.60 4.74
H = 1.15 Ex 10.0 1.10 (0.40–2.90) 1.01 10.39 8.62
SE(H) = 1.46 Ex 32.5 0.60 (0.30–1.50) 1.00 17.71 21.71
v2(ﬁt) = 2.21 (6 DF) p = 0.90 Never 1.00 1.00 18.37 16.04
2: ACROSS F 15+ Current 6.30 (3.20–12.30) 4.86 84.50 84.47
Ex 3.0 2.10 (0.60–7.00) 1.66 5.69 5.76
H = 1.18 Ex 10.0 1.50 (0.60–4.00) 1.01 10.02 9.17
SE(H) = 1.07 Ex 32.5 1.90 (0.80–4.90) 1.00 12.64 9.93
v2(ﬁt) = 2.06 (6 DF) p = 0.91 Never 1.00 1.00 17.61 21.11
3: BRHS M 40–59 Current 3.70 (2.00–6.90) 2.65 64.15 64.19
Ex 3.5 1.80 (0.80–4.40) 1.26 9.41 9.24
Ex 8.5 1.20 (0.40–3.30) 1.02 4.82 5.73
H = 1.32 Ex 15.5 1.80 (0.80–4.40) 1.00 9.41 7.32
SE(H) = 1.13 Ex 29.5 2.10 (0.90–4.80) 1.00 10.03 6.69
v2(ﬁt) = 3.69 (3 DF) p = 0.30 Never 1.00 1.00 11.68 16.34
6 + 7: CPS II M 30+ Current 2.26 (1.95–2.61) 2.24 339.77 337.17
Ex 0.5 2.48 (1.73–3.55) 2.19 32.08 28.33
Ex 2.0 1.23 (0.61–2.38) 2.04 9.03 14.93
Ex 4.5 1.48 (1.02–2.14) 1.83 29.69 36.77
Ex 8.5 1.88 (1.43–2.47) 1.58 59.67 50.13
H = 7.71 Ex 13.5 1.30 (0.97–1.73) 1.37 52.52 55.34
SE(H) = 2.23 Ex 33.0 1.06 (0.86–1.32) 1.06 105.42 105.45
v2(ﬁt) = 6.54 (3 DF) p = 0.09 Never 1.00 1.00 391.42 391.49
8 + 9: CPS II F 30+ Current 2.11 (1.62–2.75) 2.20 73.15 73.15
Ex 1.5 0.49 (0.16–1.52) 1.00 2.99 5.90
Ex 4.5 0.74 (0.24–2.30) 1.00 3.03 3.93
Ex 8.5 0.69 (0.26–1.84) 1.00 4.06 5.66
H = 0.04 Ex 13.5 0.72 (0.32–1.63) 1.00 5.95 7.91
SE(H) = 258.75 Ex 33.0 0.86 (0.50–1.51) 1.00 13.13 14.55
v2(ﬁt) = 3.53 (3 DF) p = 0.32 Never 1.00 213.54 204.75
10: DONNAN M + F 20–87 Current 3.70 (2.30–5.95) 3.49 87.36 85.76
Ex 1.125 3.20 (1.20–6.80) 3.37 15.81 16.12
Ex 3.5 3.10 (1.40–6.80) 3.12 19.23 19.32
H = 15.11 Ex 7.5 2.10 (0.95–5.00) 2.77 13.69 15.47
SE(H) = 7.35 Ex 30.0 1.70 (1.00–2.90) 1.63 38.89 38.11
v2(ﬁt) = 0.64 (7 DF) p = 1.00 Never 1.00 1.00 61.74 61.90
14: HONJO F 40–79 Current 1.69 (1.43–2.01) 1.69 155.24 154.60
Ex 1.0 1.24 (0.40–3.86) 1.56 2.97 3.75
Ex 3.5 1.27 (0.60–2.69) 1.34 6.88 7.26
Ex 7.5 1.31 (0.73–2.35) 1.15 11.22 9.91
H = 3.44 Ex 12.5 0.86 (0.36–2.08) 1.06 4.98 6.09
SE(H) = 4.07 Ex 32.5 1.14 (0.64–2.01) 1.00 11.94 10.54
v2(ﬁt) = 0.76 (3 DF) p = 0.86 Never 1.00 1.00 1068.32 1069.41
15: JAMROZ M 65–79 Current 2.15 (1.38–3.33) 2.01 31.57 29.98
(continued on next page)
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Table 4 (continued)
Block: studya Sexb Agec Smoking group Years quit RR (95%CI)d Fitted RR Cases observede Cases ﬁttedf
Ex 3.0 2.11 (1.22–3.67) 1.90 16.39 14.98
Ex 8.5 1.57 (0.88–2.78) 1.72 14.74 16.45
H = 17.74 Ex 15.5 1.20 (0.67–2.17) 1.55 14.02 18.42
SE(H) = 10.38 Ex 35.0 1.33 (0.95–1.86) 1.26 102.51 98.54
v2(ﬁt) = 1.75 (3 DF) p = 0.62 Never 1.00 1.00 49.74 50.61
19: KONDO M 20–61 Current 2.17 (1.09–4.35) 2.02 50.86 50.86
H = 0.88 Ex 2.0 1.30 (0.27–6.40) 1.21 1.81 1.81
SE(H) = 2.44 Ex 22.5 1.17 (0.47–2.92) 1.00 9.00 8.26
v2(ﬁt) = 0.12 (3 DF) p = 0.99 Never 1.00 1.00 9.46 10.20
20: LONGST M + F 18+ Current 6.01 (3.36–10.73) 4.90 55.20 55.20
Ex 0.5 2.40 (0.80–7.30) 1.96 5.74 5.74
H = 0.25 Ex 5.5 2.70 (1.20–5.80) 1.00 13.96 8.07
SE(H) = 0.20 Ex 30.0 1.10 (0.50–2.50) 1.00 10.11 11.00
v2(ﬁt) = 5.98 (6 DF) p = 0.43 Never 1.00 1.00 28.49 33.48
21: NURSES F 30–55 Current 2.78 (2.32–3.33) 2.79 255.72 254.91
(all stroke) Ex 2.5 1.75 (1.25–2.44) 1.82 41.01 42.30
Ex 7.5 1.14 (0.78–1.67) 1.17 29.50 30.13
Ex 12.5 1.17 (0.79–1.73) 1.04 28.12 24.81
H = 2.21 Ex 17.5 1.22 (0.85–1.75) 1.01 34.69 28.41
SE(H) = 0.92 Ex 27.5 0.89 (0.69–1.14) 1.00 83.19 93.03
v2(ﬁt) = 2.86 (3 DF) p = 0.41 Never 1.00 1.00 220.87 219.49
TOTAL Current 1260.23 1252.98
Ex <2 59.58 59.85
Ex 2- < 5 146.78 161.02
Ex 5- < 10 151.65 141.55
Ex 10- < 15 111.97 111.93
Ex 15- > 20 58.12 54.16
Ex 20+ 414.56 417.82
Never 145.08 146.73
23: NURSES F 30–55 Current 5.00 (3.19–7.84) 4.76 70.89 72.47
(subarachnoid haemorrhage) Ex 1.0 5.60 (2.44–12.87) 3.99 7.07 5.40
Ex 3.5 3.20 (1.11–9.19) 2.68 3.99 3.58
H = 3.01 Ex 10.0 1.20 (0.44–3.25) 1.38 4.54 5.59
SE(H) = 1.73 Ex 25.0 1.55 (0.71–3.41) 1.01 8.14 5.70
v2(ﬁt) = 1.81 (3 DF) p = 0.61 Never 1.00 1.00 25.84 27.72
24: NURSES F 30–55 Current 2.27 (1.74–2.97) 2.27 123.40 123.43
(ischaemic stroke) Ex 1.0 1.23 (0.58–2.60) 1.20 7.36 7.22
Ex 3.5 0.52 (0.18–1.51) 1.00 3.55 6.80
Ex 7.5 1.25 (0.67–2.32) 1.00 11.19 8.95
H = 0.38 Ex 12.5 1.66 (0.89–3.10) 1.00 10.98 6.62
SE(H) = 0.40 Ex 25.0 0.82 (0.48–1.39) 1.00 15.72 19.20
v2(ﬁt) = 5.48 (3 DF) p = 0.014 Never 1.00 1.00 95.57 95.54
a For each block, the block number and study reference code is shown. Also shown in this column is the estimate of half-life, H, its standard error, SE(H), and the chisquared
value for ﬁt of the model, v2(ﬁt), based on twice the difference in log-likelihood between the ﬁtted model and the best-ﬁt model.
b Apart from the sex of the subjects considered in the block, the entries in the column also show the DF for v2(ﬁt).
c Apart from the age group of the subjects considered in the block, the entries in the column also show the probability, p, value associated with v2(ﬁt) and its DF.
d The source of these data is as follows: Blocks 1,2,3,10,15,19,21-RRs and CIs as given, Blocks 6,7,8,9-RRs by level of consumption given, with CIs estimated from numbers
and person-years. For combined blocks 6 + 7 and 8 + 9, the RRs and CIs were estimated from the pseudo-numbers for the individual block, Blocks 14,20-RRs and CIs given with
current smoker base recalculated with a never smoker base using the pseudo-numbers.
e Estimated pseudo-numbers of cases (Hamling et al., 2008). Corresponding values for the controls and at risk population are available on request. Fitted values of the other
parameters A and B are given in Additional ﬁle 1.
f Corresponding values for the controls are available on request.
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recorded smoking habits, the fact that some studies report quit
time as recorded at baseline while others update it from repeat
interviews or with increasing length of follow-up, the effects of re-
verse causation, difﬁculties in estimating midpoints of time inter-
vals, the use of pseudo-numbers, and the fact that the method
used cannot include RRs adjusted for other smoking variables.
We do not discuss these issues further here. Rather, we emphasise
the main problems speciﬁc to stroke, and the conclusions to be
drawn.
Problems with the stroke data relate to the limited number of
studies, 13 versus 23 for IHD, and that, for almost half the data
blocks originally examined, the current smoker RR was quite low
(<1.40), the method either failing to produce estimates at all or
producing highly variable estimates of H. As seen in Table 3, some
blocks showed no signiﬁcant association with current smoking atall, and it is therefore unsurprising that, in these circumstances,
reliable estimates of H could not be obtained. This problem is far
severer for stroke, where nine of 22 (41%) current smoker RRs were
<1.40, than for IHD, where only 2 of 42 (5%) were.
Because of these difﬁculties, we restricted attention in our main
analyses to blocks where the current smoker RR was P1.40. Also,
in CPS II, we restricted attention to data regardless of amount
smoked, due to difﬁculties in ﬁtting the model to separate blocks
for lighter and heavier smokers. This left only 11 blocks, as com-
pared to 41 for IHD, with numbers of cases per block in quitters
typically less for stroke than for IHD.
Based on the data from these blocks, three observations can be
made. Firstly, there was no evidence at all of lack of ﬁt to the mod-
el. While somewhat reassuring, note that numbers of cases of
stroke in quitters were sometimes quite small (<50 in seven
blocks) and power to detect misﬁt would be limited.
Forest plot of half-life estimates 
0.25 0.50 4.00 32.00 64.001.00 16.00
Block: Study Half lifeHalf life
95% CI95% CI
  1:ACROSS,M 1.15 (0.10, 13.87)
  2:ACROSS,F 1.18 (0.20, 7.00)
  *3:BRHS 1.32 (0.25, 7.11)
  *6+7:CPSII,M 7.71 (4.27, 13.92)
  *8+9:CPSII,F 0.04 (*,*)
  10:DONNAN 15.11 (5.82, 39.22)
  *14:HONJO 3.44 (0.34, 34.99)
  *15:JAMROZ 17.74 (5.64, 55.82)
  *19:KONDO 0.88 (0.00, 203.28)
  20:LONGST 0.25 (0.05, 1.16)
  *21:NURSES 2.21 (0.98, 5.01)
Total (95% CI) 
*prospective study
4.78 (2.17, 10.50)
Fig. 1. Forest plot of half-life estimates. Table 4 presents results of inverse-variance weighted analysis of log H based on 11 blocks, with the estimates converted back to the
original scale by taking exponentials. The individual study estimates and the 95%CI are shown in the ﬁgure, both numerically, and graphically on a logarithmic scale. In the
graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the weight (inverse-variance of log H). Arrows indicate
where the CI extends outside the range indicated. Also shown is the combined estimate, based on inverse-variance weighted analysis of log H. This is represented by a
diamond of standard height, with the width indicating the 95%CI.
Table 5
Weighteda estimates of H by various block characteristics.
Characteristic Level Nb pc H (95%CI)
All All 11 – 4.78 (2.17–10.50)
Study type Case–control 4 0.62 3.47 (0.68–17.76)
Prospective 7 5.34 (2.04–14.03)
Sex Male 5 0.39 7.06 (2.35–21.21)
Female 4 2.09 (0.43–10.21)
Combined 2 4.89 (0.79–30.36)
Continent North America 4 0.64 3.86 (1.25–11.96)
Europe 1 1.32 (0.02–84.80)
Asia 2 2.79 (0.01–544.79)
Australia 4 9.45 (1.87–47.60)
Publication year Before 1990 1 0.38 15.11 (1.78–127.94)
1990–1994 3 4.98 (1.44–17.18)
From 1995 7 3.13 (0.91–10.72)
Age at baseline <50 3 0.34 1.98 (0.41–9.65)
50–59 5 3.47 (0.79–15.19)
60–69 2 7.71 (2.12–27.97)
70+ 1 17.74 (1.46–215.66)
Smoking product Cigarettesd 6 0.25 3.55 (1.37–9.20)
Any producte 5 8.77 (2.25–34.20)
Current smoker RR 1.50–1.99 1 0.22 3.44 (0.03–148.65)
2.00–2.99 5 5.97 (2.42–14.77)
3.00–3.99 3 6.85 (1.36–34.56)
4.00+ 2 0.48 (0.04–5.36)
Cases in quitters <100 8 0.58 2.98 (0.68–13.01)
100–249 2 4.46 (0.93–21.37)
250–499 1 7.71 (1.91–31.10)
a Based on inverse-variance weighted analysis of log H, with the estimates converted back to the original scale by taking exponentials.
b Number of blocks.
c Probability value for difference between groups.
d Cigarettes regardless of pipe and cigar smoking.
e Smoked cigarettes, pipes and/or cigars.
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2.17–10.50) years was similar to that for IHD of 4.40 (95%CI
3.26–5.95) years. Given both are vascular diseases, this is perhaps
consistent with expectation. Both estimates are lower than we
reported for lung cancer (Fry et al., 2013) of 9.93 (95%CI 9.31–
10.60), a disease where effects of smoking are more long-lasting.Third, there was clear evidence of heterogeneity in H, not read-
ily explicable by other factors. This conclusion was similar to that
for IHD, though there age of subjects and current smoking RR were
associated with the value of H. As for IHD, it is difﬁcult to place
great faith in an estimate of H of about 4–5 years when some stud-
ies present data indicating a much shorter H and some a much
Table 6
Comparison of ﬁtted H values and goodness-of-ﬁt for the main and sensitivity analyses.a
Blockb Main analysisc Sensitivity analysis Ad Sensitivity analysis Be Sensitivity analysis Cf Sensitivity analysis Dg
1 1.15 3.20 1.15 1.15 1.15
2 1.18 2.33 1.18 1.18 1.18
3 1.32 0.40 1.32 1.32 1.32
6 + 7 7.71 7.80 7.67 6.85 7.89
8 + 9 0.04 0.12 0.12 0.04 0.04
10 15.11 14.98 15.25 9.91 19.77
14 3.44 3.67 3.72 3.64 3.42
15 17.74 18.83 17.74 12.34 20.51
19 0.88 8.17 0.88 0.88 0.88
20 0.25 3.54 4.22 0.25 0.25
21 2.21 2.62 2.21 2.20 2.21
Totalh 4.78 6.40 5.55 4.61 4.80
a The values shown in the table are the ﬁtted H values. Where there is evidence of misﬁt, this would have been indicated by: ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, but no misﬁt
occurred.
b See Table 4 for details of the blocks.
c Results as shown also in Table 4.
d Omitting the estimate in each block with the lowest quitting period. Estimates in square brackets are those for blocks where this omission left only a single RR for quitters.
e Counting estimates with an upper limit of quitting time up to 2 years as applying to current smokers. Dashes indicate where this did not affect the data considered.
f Midpoint time for the ﬁnal, open-ended, period of quitting which is estimated as the mean of the lower limit and either 30 years or the upper limit of the age range
studied minus 30 years, if this is smaller than 30 years. Dashes indicate where this did not affect the data considered.
g Midpoint time for the ﬁnal, open-ended, period of quitting which is estimated as the mean of the lower limit and either 70 years or the upper limit of the age range
studied minus 70 years, if this is smaller than 70 years. Dashes indicate where this did not affect the data considered.
h The inverse-variance weighted mean of log H, converted back to the original scale.
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where one wishes to predict the effect of switching to lower risk
products by time of switch (based on the adaptation of the model
referred to in the IHD paper (Lee et al., 2012)), the overall estimates
derived for stroke may be the most suitable ones to use.
As the RR associated with current smoking varies by type of
stroke (Kawachi et al., 1993; US Surgeon General, 2004), it is pos-
sible that H might vary by type of stroke. Unfortunately, the data
available to test this are extremely limited, most of the evidence
on risk by time of quit being for overall risk of stroke. Limited evi-
dence suggests that, for subarachnoid haemorrhage, the type most
strongly associated with smoking, the decline in excess risk might
be relatively more rapid, with a shorter H, than our overall esti-
mate suggests. However, more evidence would be needed before
ﬁrm conclusions could be drawn.
5. Conclusions
The data on quitting smoking and stroke are rather too limited,
and the effect of smoking too weak, to give good insight into the
value of the negative exponential model. However, when consid-
ered in conjunction with the corresponding analyses for IHD (Lee
et al., 2012) and for lung cancer (Fry et al., 2013), they support
the idea that, for a number of smoking-related diseases, the decline
in excess risk following quitting can be quite well approximated
using the model. The half-life seems to be similar for stroke and
IHD.
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